Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2023-03-13 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-03-13 English
SC 13G/A
Major Shareholding Notification
2023-02-14 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the registrant, incorporation of previous filings by reference, exhibits related to corporate governance documents, legal opinions, and consents. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing related to securities registration rather than a financial report or announcement. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 7702 characters, which is consistent with a full registration statement rather than a brief announcement.
2023-02-06 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-26 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-01-26 English
DEFA14A
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Leap Therapeutics, Inc. dated January 17, 2023. It details the completion of a merger acquisition of Flame Biosciences, Inc., including the terms of the merger agreement, issuance of shares, stockholder meeting proposals, and appointment of new directors to the board as a result of the merger. The document includes detailed descriptions of the merger transaction, stock issuance, and changes in board membership. This type of filing is a current report disclosing material events, specifically a merger and related management changes. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). The document is not a proxy statement, annual report, or earnings release, but a current report focused on merger activity and related corporate governance changes. Therefore, the appropriate classification is 'TAR' with high confidence.
2023-01-23 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.